Full Press Release Details
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis.
ARGX
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
Key Takeaway: argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis